Startups
Our mission is to develop lifesaving accessible immunotherapies for the most prevalent diseases
Overview
Location
United States, New Jersey, Warren Township
Employees
501-1000
Phone
+1 877-838-6436
Founded date
2020
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 6, 2025 | Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology | Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy... |
| Jun 2, 2025 | Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships | Tevogen today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio’s proprietary ExacTcell™ t... |
| Mar 3, 2025 | Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations | Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI. Efficient operations with operating expenses of $9.7 million... |
| Mar 3, 2025 | Tevogen Bio To Receive $8 Million In Grant Funding | Tevogen Bio, a clinical-stage specialty immunotherapy biotech, announced in January 2025 that it received $2 million in non-dilutive grant funding from KRHP. An additional $8 million will be contributed, contingent on KRHP’s review of the c... |
| Mar 3, 2025 | Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations | Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI.Efficient operations with operating expenses of $9.7 million ... |
| Feb 14, 2025 | Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency | WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company’s 2024 financing activity at th... |
| Jan 28, 2025 | Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding | The grant funding will further Tevogen Bio’s mission to develop therapies for treatment of cancers and viral infections. Tevogen Bio may also utilize the grant funding to further expand its artificial intelligence effort. This grant is in a... |
| Jun 11, 2024 | Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts | Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy ... |
| May 10, 2024 | Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives | Supports expansion of Tevogen’s ExacTcell™ platform toward additional clinical trials Bolsters a financial path to positive cashflow and minimizes dilution WARREN, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” ... |
Show more
Reviews 0
FAQ about TEVOGEN BIO
When was TEVOGEN BIO founded?
TEVOGEN BIO was founded in 2020.
What has the press written about TEVOGEN BIO?
Parsers VC has collected 14 articles mentioning TEVOGEN BIO, among them “Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology” (Aug 6, 2025) and “Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships” (Jun 2, 2025).
Is TEVOGEN BIO still active?
Yes, TEVOGEN BIO is active; its latest activity on Parsers VC dates from Sep 25, 2025.